The World Health Organisation (WHO) released the second edition of its policy guidance on the deployment of medical devices. This update represents a significant evolution from the first edition, moving away from a narrow focus on regulation and procurement toward a comprehensive medical device ecosystem framework. The guidance reflects changes in global health priorities, technological advancement, and lessons learned from recent public health emergencies. It is designed to support countries in building resilient, equitable, and sustainable systems that govern the full lifecycle of medical devices, from innovation and research through deployment, maintenance, and eventual decommissioning. For policymakers, regulators, and health system leaders, the second edition provides a structured blueprint for aligning medical device policy with universal health coverage and the Sustainable Development Goals.
Why the Second Edition Was Needed
Since the publication of the first edition, the global health landscape has changed substantially. Health priorities have shifted from the Millennium Development Goals to the Sustainable Development Goals, placing greater emphasis on universal health coverage, equity, sustainability, and system resilience. At the same time, the pace of technological change has accelerated. Digital health platforms, artificial intelligence, software-based devices, wearables, and connected systems are now integral to healthcare delivery. Recent health emergencies highlighted vulnerabilities in supply chains, regulatory capacity, and preparedness. The second edition responds directly to these realities by expanding the scope of policy guidance beyond regulatory compliance to address governance, implementation, and system-wide integration.
From Regulation to a Medical Device Ecosystem
A central theme of the updated guidance is the concept of a medical device ecosystem. Rather than treating devices as isolated products subject only to regulatory approval, the WHO frames them as part of an interconnected system that includes research and development, health technology assessment, regulation, procurement, distribution, maintenance, training, digital infrastructure, and disposal. Effective policy must address each of these elements in a coordinated way. Fragmented approaches that focus only on approval or procurement risk inefficiency, waste, and inequitable access. By contrast, an ecosystem approach supports continuity, sustainability, and better health outcomes.
New and Expanded Policy Areas
The second edition introduces several new sections that reflect emerging priorities. Sustainability is addressed explicitly, recognising the environmental impact of medical devices across their lifecycle. Digital health is treated as a core system enabler rather than an add-on. Participatory governance is emphasised, encouraging engagement with clinicians, patients, communities, and other stakeholders. Public health emergency preparedness is strengthened, incorporating lessons from pandemics and other crises. Together, these additions broaden the guidance from technical policy to practical system stewardship.
Updated Regulatory and Technology Management Frameworks
The guidance updates regulatory concepts to reflect modern practice. Health Technology Assessment and Health Technology Management are integrated more explicitly into national policy frameworks. These tools support evidence-based decision-making on which devices to prioritise, how to allocate resources, and how to manage technologies over time. The guidance also aligns with recent WHO medical device technical series publications, ensuring consistency with current WHO standards and recommendations. This alignment helps countries avoid outdated approaches and supports harmonisation across regions.
Standardising Medical Device Nomenclature
A notable addition in the second edition is a dedicated section on medical device nomenclature. Consistent naming and classification of devices are essential for regulation, procurement, post-market surveillance, and international comparison. The guidance encourages the adoption of standardised nomenclature systems to improve data quality, traceability, and interoperability. Standardisation also supports more effective health technology assessment and market oversight by enabling clearer comparisons across products and jurisdictions.
Implementation and Measurement
Unlike earlier guidance that focused primarily on policy intent, the second edition places strong emphasis on implementation. It provides practical guidance on how to operationalise medical device policy strategies within health systems. This includes governance structures, institutional roles, capacity building, and coordination mechanisms. The guidance also introduces indicators and evaluation systems to measure progress and impact. By embedding monitoring and evaluation, countries can assess whether policies are delivering improved access, safety, and efficiency rather than existing only on paper.
Digital Health and AI as System Enablers
One of the most significant expansions in the second edition is the inclusion of a comprehensive section on digital health and artificial intelligence. The WHO recognises that digital systems, electronic health records, data analytics, and AI-powered tools have the potential to transform healthcare delivery, public health surveillance, research, and system management. These technologies can improve efficiency, support evidence-based decision-making, and extend care to underserved populations. However, the guidance is clear that these benefits are not automatic and depend on strong governance.
Governance Principles for Digital Health and AI
The WHO places ethics, human rights, and equity at the centre of digital health and AI policy. A national data protection framework is identified as foundational. Such a framework should define how health data are collected, stored, shared, processed, anonymised when appropriate, and accessed. Oversight mechanisms such as independent data protection authorities, along with clear accountability measures, are essential to maintain trust. The guidance distinguishes between aggregate data and personal data and stresses that safeguards must be appropriate to each category.
AI systems must be designed and deployed in ways that avoid reinforcing existing inequalities or biases. High-quality, representative datasets are critical. Transparency and explainability are required throughout the lifecycle of AI tools, from development and validation to deployment and post-deployment monitoring. Importantly, AI should support human decision-making rather than replace it. Clinicians and patients must understand how AI influences care decisions, ensuring that responsibility and accountability remain clear.
Interoperability and Data Standards
The guidance highlights the importance of data interoperability and standardised coding systems. Interoperable systems enable integrated care, more reliable analytics, and better public health monitoring. Without common standards, digital health investments risk fragmentation and limited impact.
Benefits of a Governed Digital Health Ecosystem
When implemented with strong governance, digital health and AI can deliver substantial benefits. Aggregated data support better public health planning and resource allocation. Clinical decision support tools can enhance diagnostics and treatment, particularly in settings with limited specialist availability. Secure data sharing enables coordinated care across providers. High-quality standardised data underpin research, surveillance, and policy evaluation, strengthening health system learning and adaptation.
Risks and Challenges
The guidance also addresses risks candidly. Weak protections can lead to privacy breaches and misuse of sensitive health data, undermining public trust. Biased or unrepresentative datasets can produce inequitable or unsafe AI outcomes. Lack of regulation or oversight may allow ineffective or harmful technologies to proliferate. Infrastructure and capacity gaps risk widening inequalities if digital tools benefit only well-resourced settings. Poor data quality undermines the reliability of analytics and decision support. These risks underscore the need for deliberate, policy-led implementation.
Policy Recommendations for Ministries of Health
The WHO provides clear recommendations for national authorities. Governments should establish or strengthen health-specific data protection and privacy laws. Standards for data interoperability and system integration should be adopted nationally. AI tools should undergo rigorous evaluation before deployment and be subject to ongoing monitoring and accountability mechanisms. Equity considerations must be embedded to ensure that digital health initiatives do not exacerbate disparities. Stakeholder engagement is essential, with patients, communities, healthcare workers, and technical experts involved in governance, design, and oversight.
Implications for Global Health Systems
The second edition of the WHO guidance positions medical device policy as a core component of health system strengthening. By integrating regulation, digital health, sustainability, and governance, it offers a coherent framework for countries at different stages of development. The guidance supports not only safe and effective use of medical devices but also resilience, equity, and long-term system performance.
LFH supports organisations, regulators, and health system stakeholders in interpreting global policy guidance and translating it into practical regulatory and implementation strategies. Our team helps clients align medical device, digital health, and AI initiatives with international best practice while maintaining regulatory rigour and system-level impact.
FAQs – WHO Medical Device Policy Guidance
Is the WHO guidance legally binding?
No, it is policy guidance intended to support national decision-making.
Does the second edition replace the first edition?
Yes, it supersedes the earlier guidance and reflects updated priorities.
Does the guidance apply to digital health and AI tools?
Yes, digital health and AI are explicitly addressed as part of the medical device ecosystem.
Is sustainability a new focus area?
Yes, environmental sustainability is newly integrated into device policy considerations.
Does the guidance include implementation advice?
Yes, it provides practical guidance, indicators, and evaluation approaches.
Who should use this guidance?
Ministries of health, regulators, policymakers, and health system leaders.
